We are live on
!
Find out more
PCM
Puissance Capital Management Portfolio holdings
AUM
$17.3M
1-Year Est. Return
149.36%
This Fund
S&P 500
This Quarter
Est. Return
+58.92%
1 Year Est. Return
+149.36%
3 Year Est. Return
+115.5%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$123M
AUM Growth
+$35.3M
(+40%)
Cap. Flow
-$4.44M
Cap. Flow
% of AUM
-3.61%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$3.73M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$716K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.92% |
| 2 | Healthcare | 12.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHRN
1
ChronoScale Holdings
CHRN
$2.69B
| $51.5M | 41.92% |
91,266
| – | – |
|
|
VRAY
2
DELISTED
ViewRay, Inc.
VRAY
| $50.6M | 41.13% |
6,842,975
| – | – |
|
|
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
| $7.97M | 6.49% |
3,020,596
-1,478,756
| -33% | -$3.73M |
|
|
TCON
4
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $6.3M | 5.13% |
23,009
| – | – |
|
|
BLPH
5
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $5.42M | 4.41% |
553,250
| – | – |
|
6
Corvus Pharmaceuticals
CRVS
$1.1B
| $1.15M | 0.93% |
284,869
| – | – |
|
|
7
State Street SPDR S&P Biotech ETF
XBI
$10B
| – | – |
-9,986
| Closed | -$716K |
|
Similar funds
FM
IAM
FP
AF
TCS
JJ
PCM
NC
Puissance Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Puissance Capital Management held 7 positions worth $123M, up 40% from $87.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Puissance Capital Management withdrew a net $4.44M in Q1 2019, closing 1 position and reducing 1 holding. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $716K position sold in full.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 29% a quarter earlier, followed by Healthcare.
- Puissance Capital Management's biggest Q1 2019 reduction was Kadmon Holdings, Inc., cutting an estimated $3.73M.
- Puissance Capital Management fully exited State Street SPDR S&P Biotech ETF in Q1 2019, selling an estimated $716K.
- Puissance Capital Management's ten largest holdings make up 100% of its $123M portfolio in Q1 2019.
- Puissance Capital Management opened 0 new positions and closed 1 in Q1 2019.
- Puissance Capital Management's portfolio value rose 40% quarter-over-quarter to $123M.
Based on Puissance Capital Management's 13F filing for Q1 2019, filed 14 May 2019.